Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
In some parts of the world mushrooms have had a central role in religious ritual ceremonies. Ethnomycological studies among the Indian tribes of Mexico - the Aztecs and the Chichimecas - revealed the mushrooms to be hallucinogenic. Chemists from a leading Pharmaceutical company took over, isolated and described the mushroom alkaloid psilocybin, that upon dephosphorylation after collection of the mushroom or in the human body, form psilocin that is the active hallucinogenic compound. For a long time psilocybin/psilocin was expected to become a constituent of psychedelic drugs useful for treatment of specific psychoses. As the effect of psilocybin/psilocin resembles that of LSD the isolated compound, as well as mushrooms containing the compound, became popular among recreational users of hallucinogenic drugs in Western America, and from there the habit of using these mushrooms have spread around the world. Psilocybin/psilocin is legally prohibited in many countries which usually treat the compound as a narcotic drug. Some countries also prohibit the use of some or all psilocybin-containing mushrooms. In this respect, the legal situation differs between Nordic countries. Although psilocybin-containing mushrooms are not what Nordic mushroom pickers are trying to find as food or food supplement, there is a risk, admittedly small, that these mushrooms accidentally will be collected. At the present situation, this may be a legal problem in some Nordic countries. This document aims at identifying when this might be the case without going into legal interpretations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“In a double-blind study on hallucinogen-naïve subjects, Griffiths et al. (2006) recently showed that psilocybin under supportive conditions give rise to experiences similar to spontaneously”
BackgroundPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 1×
“The psychotomimetic effects observed after exposure to psilocybin/psilocin result from stimulation of Occurrence and use of psilocybin-containing hallucinogenic mushrooms 76 5-hydroxytryptamine receptors, especially the 5-HT2a receptor (Strassman, 1992; Vollenweider et al., 1998).”
BackgroundThe pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465 · cited 3×
“These psychic effects include stimulation, enhanced ability for introspection and altered psychological functioning in the direction of Freudian primary processes, also known as hypnagogic experience and dreams (Passie et al., 2002).”
BackgroundInfluentialHasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444 · cited 1×
“…of psilocybin, Gouzoulis et al. (1999b) found no increase of global brain metabolism after per oral exposure to 0.2 mg/kg psilocybin, whereas Vollenweider et al. (1997) found a general increase of cortical metabolism in various parts of the brain after slightly higher exposure levels (0.26…”
BackgroundInfluentialVollenweider, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00108-0 · Cited by 305 · cited 1×
“(Parashos, 1976–1977; Spitzer et al., 1996; Vollenweider et al., 1999).”
Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim
Hofmann, A., Heim, R., Brack, A., & Kobel, H. (1958) · Experientia · doi:10.1007/bf02159243 · Cited by 282
Gouzoulis-Mayfrank, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00089-x · Cited by 219
Cross tolerance between LSD and psilocybin
Isbell, H., Wolbach, A. B., Wikler, A., & Miner, E. J. (1961) · Psychopharmacologia · doi:10.1007/bf00407974 · Cited by 137
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines
Blair, J. B., Kurrasch-Orbaugh, D., Marona-Lewicka, D., Cumbay, M. G., Watts, V. J., Barker, E. L., & Nichols, D. E. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000339w · Cited by 131
Cited by
Psychedelics and mental health: a population study
Krebs, T. S., & Johansen, P.-Ø. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063972 · Cited by 347
Motives and Side-Effects of Microdosing With Psychedelics Among Users
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., & Kuypers, K. P. C. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz029 · Cited by 126
Over 30 million psychedelic users in the United States
Krebs, T. S., & Johansen, P.-Ø. (2013) · F1000Research · doi:10.12688/f1000research.2-98.v1 · Cited by 124
Van Court, R. C., Wiseman, M. S., Meyer, K. W., Ballhorn, D. J., Amses, K. R., Slot, J. C., Dentinger, B. T. M., Garibay-Orijel, R., & Uehling, J. K. (2022) · Fungal Biology · doi:10.1016/j.funbio.2022.01.003 · Cited by 94
Gotvaldová, K., Hájková, K., Borovička, J., Jurok, R., Cihlářová, P., & Kuchař, M. (2021) · Drug Testing and Analysis · doi:10.1002/dta.2950 · Cited by 67
Metadata
- Authors
- Andersson, C., Gry, J., & Kristinsson, J.
- Venue
- TemaNord
- Publisher
- Nordic Council of Ministers
- Published
- 2009-05-19
- ISSN
- 0908-6692 (ISSN-L)
- OpenAlex
- W2099103834
- Cited by
- 41
- References
- 11
- FWCI
- 0.59
- Type
- book
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids. https://app.cochat.ai/papers/10.6027/tn2008-606
- The paper
- Andersson, C., Gry, J., & Kristinsson, J. (2009). Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids. TemaNord. https://doi.org/10.6027/tn2008-606
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.